The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pilot study of gemcitabine, nab-paclitaxel, PEGPH20, and rivaroxaban for advanced pancreatic adenocarcinoma: An interim analysis.
 
Kenneth H. Yu
Consulting or Advisory Role - celgene; Merck Serono; Merrimack
 
Simon Mantha
No Relationships to Disclose
 
Catherine Tjan
No Relationships to Disclose
 
Erica S. Kaufmann
No Relationships to Disclose
 
Robin Brenner
No Relationships to Disclose
 
Maeve Aine Lowery
Consulting or Advisory Role - Agios; Celgene
 
Geoffrey Yuyat Ku
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer
Research Funding - Arog (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst); Merck (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune
 
Nitya Prabhakar Raj
No Relationships to Disclose
 
Marina Shcherba
No Relationships to Disclose
 
Zoe Goldberg
No Relationships to Disclose
 
Jia Li
No Relationships to Disclose
 
Alice Zervoudakis
No Relationships to Disclose
 
Audrey M. Hamilton
No Relationships to Disclose
 
Elizabeth Won
No Relationships to Disclose
 
Antonio Ucar
No Relationships to Disclose
 
Richard K. G. Do
No Relationships to Disclose
 
Eileen Mary O'Reilly
Consulting or Advisory Role - Aduro Biotech; Agios (I); ASLAN Pharmaceuticals (I); Astellas Pharma (I); AstraZeneca (I); Bayer (I); Blueprint Medicines (I); Boston Scientific (I); Bristol-Myers Squibb; Bristol-Myers Squibb (I); CASI Pharmaceuticals (I); Celgene; Celsion (I); Delcath Systems (I); Eisai (I); Gilead Sciences; Halozyme (I); IntegraGen (I); Ipsen (I); Janssen; MedImmune; Merck (I); Merrimack; New B Innovation (I); Newlink Genetics; Onxeo (I); Sanofi; Servier (I); Silenseed; Sillajen (I); Sirtex Medical (I); VAXIMM; Vicus Therapeutics; Westhaven (I)
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Incyte (Inst); Mabvax (Inst); Momenta Pharmaceuticals (Inst); OncoMed (Inst)